360° Coverage : Novo Hiring New Reps, Now They Need Something To Sell

2 Updates
Novo Hiring New Reps, Now They Need Something To Sell

Novo Hiring New Reps, Now They Need Something To Sell

Feb 6 2014, 1:43pm CST | by

In news that should come as a surprise to no one, it looks like Roche Diabetes Care is about to undergo yet another restructuring, which is really a nice way of saying more layoffs are coming....

Filed under: news

 
 
 

32 weeks ago

Novo Hiring New Reps, Now They Need Something To Sell

Feb 6 2014, 1:43pm CST | by

In news that should come as a surprise to no one, it looks like Roche Diabetes Care is about to undergo yet another restructuring, which is really a nice way of saying more layoffs are coming. Perhaps the real news here is that Roche actually has anyone left in the unit to layoff. Like everyone else in conventional blood glucose monitoring, Roche has cut costs to the bone as they desperately try and find a buyer for this beleaguered unit.

Compare this news to an article that appeared in Fierce PharmaMarketing which stated:

“When we hear about companies actually hiring reps, that’s news. Given the thousands of sales layoffs over the past several years–and recruiting focused on emerging markets, especially China–staffing up in the U.S. or Europe is out of the ordinary. When that hiring isn’t about a new drug launch, we hardly know what to make of it.

That’s just what Novo Nordisk has been doing: hiring reps by the hundred in the U.S. First, it was in anticipation of the Tresiba launch that didn’t happen in 2013, but last fall, another 350 joined the company. Couple that with 120 new nurse educators, and the Danish drugmaker has expanded its field force by almost 15%.”

Granted the diabetes drug market is not as bad as the diabetes device market, but it won’t be long before it suffers the same fate, which makes this decision by Novo Nordisk (NVO) even stranger and not just from a cost perspective. It’s a well-known fact that the fewer and fewer physicians are actually seeing sales reps. It’s also true that while the physician would like to have control over which drugs they prescribe increasingly this decision is being taken away from the physician and put in the hands of the patients insurance company.

Although pharma reps hate to hear this, the reality is their job function can be easily and more cost effectively performed by an automated or virtual system. This is increasingly true with diabetes drugs which are filled with me-too copycats that all do basically the same thing pretty much the same way. The days of pharma reps sitting with physicians reviewing the latest study data are over, the simple fact is if a physician wants information on any drug the fastest, easiest way to get it is to surf the net. Add in the fact that either by law or by cost concerns also over are the days when reps can leave behind drug samples.

Novo’s decision to continue to add reps while the competition is moving in the exact opposite direction would make sense if they actually had something new to sell. Yet with Tresiba delayed at the FDA indefinitely we can’t quite figure out what exactly these people will be doing. This is not like the old days when a company could put an army of reps into the field and see an almost impact on sales growth. Novo already has a well-established and well known product line. So again just what new stories can these reps, the lucky few who actually get to sit down with a physician, say.

Lastly there is the cost issue which is a major issue when one considers that pricing pressure continues to intensify. This move to add reps makes me believe that old habits die hard at Novo as they continue to believe that they will receive premium pricing for the products they make. There continued pursuit to have Tresiba approved in the U.S. is another example of this.

While the FDA is being overly cautious with Tresiba, the fact is even if the drug does eventually make it to market it will have a tough time given it’s likely a generic version of Lantus will be available which will drive prices even lower.

Years ago I warned everyone that the BGM market was transforming itself from a medical device to commodity market where price trumps performance. Unfortunately for BGM companies this prediction came true and as a result they are watching a once prosperous business sink into oblivion. Unable to divest themselves of these units it makes perfect sense they would cut costs to the bone and get whatever they can from these units.

Today we’ve been warning everyone that the diabetes drug market is following this same path and every indicator tells us that this prediction is also coming true. The real question is can a company like Novo avoid the mistakes made by their BGM counterparts.

Can they, unlike their counterparts, adapt to this new environment, see realistically where this market is and more importantly where it is headed?  Their continued pursuit of Tresiba with the FDA and hiring even more reps tells Diabetic Investor that history will be repeating itself. That it won’t be long before that Novo also decides that it’s time to restructure and align costs with the new realities of this market.

We realize this not welcome news to all these new reps but it is unfortunately the way it is.

Source: Forbes Business

 
Update
2

3 weeks ago

Khazanah throws MAS RM6b lifeline

Aug 29 2014 5:01pm CDT | Source: Business Times Singapore

August 30, 2014 1:15 AMKHAZANAH Nasional will inject RM6 billion (SS$2.4 billion) over three years to resuscitate loss-making Malaysia Airlines (MAS) under a recovery plan that includes even an Act of Parliament. Other key moves are migrating its operations, assets and liabilities to a new company (NewCo) and slashing ...
Source: Business Times Singapore   Full article at: Business Times Singapore
 

 
Update
1

3 weeks ago

MAS posts loss of RM307m for Q2

Aug 28 2014 5:00pm CDT | Source: Business Times Singapore

August 29, 2014 1:13 AMMALAYSIA Airlines (MAS) registered a loss of RM307 million (S$122 million) for the second quarter to end-June, but warned of worse to come in the second half when the "full financial impact of the double tragedies of MH370 a ...
Source: Business Times Singapore   Full article at: Business Times Singapore
 

 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

More Hubble observation time goes to men: Study
Washington, Sep 20 (IANS) In a disturbing trend, an internal Hubble Space Telescope (HST) study has found that in each of the past 11 observation proposal cycles, applications led by male principal investigators had a higher success rate than those led by women.
 
 
Eight members of Ebola fact-finding mission killed in Guinea
Dakar, Sep 20 (IANS/EFE) Eight members of a government team were killed with machetes and knives by residents of a village in a remote area of Guinea where they had gone to gather data about the spread of the deadly Ebola virus disease, African media outlets said.
 
 
Physicists verify Einstein's time-dilation theory
London, Sep 20 (IANS) Do you believe that a person travelling in a high-speed rocket would age more slowly than people back on Earth?
 
 
Microbial cell technology to better clean-up rural waste
Washington, Sep 20 (IANS) In a bid to help under-developed countries clean polluted water more effectively, researchers at the Washington State University (WSU) have developed a unique method to use microbes buried in pond sediment to power waste cleanup in rural areas.
 
 
 

Latest from the Network

More Hubble observation time goes to men: Study
Washington, Sep 20 (IANS) In a disturbing trend, an internal Hubble Space Telescope (HST) study has found that in each of the past 11 observation proposal cycles, applications led by male principal investigators had a...
Read more on Politics Balla
 
Voting for New Zealand general elections ends
Wellington, Sep 20 (IANS) Voting for New Zealand's general elections ended Saturday and counting of the ballots has begun. Polling stations across the country opened at 9 a.m., Xinhua reported. According to the...
Read more on Politics Balla
 
Eight members of Ebola fact-finding mission killed in Guinea
Dakar, Sep 20 (IANS/EFE) Eight members of a government team were killed with machetes and knives by residents of a village in a remote area of Guinea where they had gone to gather data about the spread of the deadly...
Read more on Politics Balla
 
China closes 1.8 mn networking accounts in porn crackdown
Beijing, Sep 20 (IANS) China has closed nearly 1.8 million social networking and instant messaging accounts since April, when it launched a campaign to purge the internet of obscene content, Xinhua reported Saturday....
Read more on Politics Balla
 
Physicists verify Einstein's time-dilation theory
London, Sep 20 (IANS) Do you believe that a person travelling in a high-speed rocket would age more slowly than people back on Earth? Giving a thrust to the "time-dilation" effect, physicists have verified a key...
Read more on Business Balla
 
Kurdish militias kill 18 IS rebels in Syria
Damacus, Sep 20 (IANS) At least 18 Islamic State (IS) militants were killed in clashes with Kurdish militias in northern Syria, the Syrian Observatory for Human Rights said Saturday. The killing of the IS fighters is...
Read more on Politics Balla
 
Microbial cell technology to better clean-up rural waste
Washington, Sep 20 (IANS) In a bid to help under-developed countries clean polluted water more effectively, researchers at the Washington State University (WSU) have developed a unique method to use microbes buried in...
Read more on Business Balla
 
Judi Dench to skip Oscars
Dame Judi Dench won't be attending the Oscars next year. The 79-year-old actress - who was nominated for Best Actress this year but missed the ceremony because of filming commitments - insists she ''loves'' the Academy...
Read more on Movie Balla
 
True love stays forever
London, Sep 20 (IANS) Only true love stays forever is a saying that has been proved to be true as British archeologists have unearthed skeletons of a couple holding hands while searching for a lost chapel in...
Read more on Politics Balla
 
Aishwarya, Freida in L'Oréal Paris' star-studded ad
Los Angeles, Sep 20 (IANS) Indian beauties Aishwarya Rai and Freida Pinto feature alongside Hollywood celebrities like Zoe Saldana, Eva Longoria, Blake Lively, Jane Fonda and Julianne Moore in a star-studded ad...
Read more on Celebrity Balla